Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484479 | 0.81 | TP53 (0.33) | USP2ALDH1A1LMNATSHRKDM4E | |
| SCHEMBL323068 | 0.81 | USP2 (0.42) | USP2ALDH1A1LMNATSHRKDM4E | |
| Acetic Acid SCHEMBL2481280 | 0.79 | KDM4E (0.31) | USP2ALDH1A1LMNATSHRKDM4E | |
| SCHEMBL1662342 | 0.79 | GAA (0.36) | CYP1A2ALDH1A1KMT2A | |
| SCHEMBL16028550 | 0.78 | KDM4E (0.36) | USP2ALDH1A1LMNATSHRKDM4E | |
| SCHEMBL10287542 | 0.75 | ALDH1A1 (0.42) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL799912 | 0.75 | KDM4E (0.37) | USP2ALDH1A1LMNATSHRKDM4E | |
| SCHEMBL14391226 | 0.75 | NPSR1 (0.37) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL25005479 | 0.74 | KDM4E (0.36) | USP2ALDH1A1LMNATSHRKDM4E | |
| SCHEMBL15578278 | 0.74 | USP2 (0.36) | USP2ALDH1A1LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| WO-2012020271-A1 | PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM | RICHTER GEDEON NYRT. (HU) | 2012-02-16 | — | — | WO | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-20050245568-A1 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245568-A1 | Process for making montelukast and intermediates therefor | CYP51A1, GPR17, CYP27A1 | CYP1A2 348/4885USP2 2738/4885ALDH1A1 443/4885 |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | CYP1A2 1851/4885USP2 982/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.